The FDA has disclosed how it intends to continue to use remote regulatory assessments (RRAs) and other alternative oversight tools employed during the COVID-19 pandemic to evaluate manufacturing facilities identified in pending premarket applications for drugs and biological products. Among the alternative facility evaluation tools used during the pandemic, according to a new... Read More